Roivant Sciences (NASDAQ: ROIV) experienced a 2.7% decline in early trading on Friday, with shares settling at $36.58, even as the company secured U.S. regulatory approval for LISRAYA, a novel oral therapy for dermatomyositis. The market's reaction erased approximately $720 million in implied equity value, suggesting investors are now focusing on the commercial hurdles ahead rather than the regulatory milestone itself.
The U.S. Food and Drug Administration (FDA) granted approval for LISRAYA (30-mg oral tablet, once daily) as the first oral treatment specifically indicated for adults with dermatomyositis, a rare autoimmune disease affecting fewer than 5,000 individuals in the United States. Historically, patients have relied on steroids and other immunosuppressive agents that were not formally approved for this condition, leaving a significant unmet need.
The approval was supported by a Phase 3 study involving 241 patients, who were randomized to receive either one of two LISRAYA dosage levels or a placebo over a 52-week period. The primary endpoint, the mean Total Improvement Score (TIS), showed a statistically significant improvement: patients on the approved dose achieved a mean TIS of 46.5, compared to 31.2 for placebo, a difference of 15.3 points. Clinical benefits emerged as early as week four and were sustained through week 52, with treated patients also reducing their steroid use more effectively than those on placebo.
With the regulatory uncertainty now resolved, the spotlight shifts to commercial execution. LISRAYA is already available through U.S. specialty pharmacies, according to Roivant's approval announcement. The company has not disclosed pricing, but it stated that eligible patients could pay as little as $0 per month, though actual revenue will hinge on insurer coverage and reimbursement dynamics.
JPMorgan analyst Brian Cheng projects that annual U.S. sales of LISRAYA could surpass $2 billion by the early 2030s, as reported by Reuters. That figure represents roughly 7.6% of Roivant's current market capitalization of $26.42 billion, underscoring the drug's commercial potential relative to the company's size.
Roivant enters the launch with a robust balance sheet, reporting $3.9 billion in cash, restricted cash, and marketable securities as of June 30. The company posted a net loss of $290.6 million for the quarter, with research and development expenses of $202 million and revenue of just $1.4 million, highlighting the capital-intensive nature of drug development.
Despite the stock's dip, the price of $36.58 remains near its 52-week high of $37.95, reflecting the market's earlier optimism. The stock opened Friday at $37.01, following a Thursday close of $37.58. The modest pullback may also be attributed to profit-taking after a recent run-up, as well as lingering concerns about reimbursement timelines and the drug's safety profile.
LISRAYA carries boxed warnings for serious infections, malignancy, major cardiovascular events, and thrombosis, which could temper prescriber enthusiasm and payer willingness. The company will need to navigate these risks while building market share in a niche but underserved patient population.
Looking ahead, key performance indicators will include prescription volumes, payer coverage decisions, and published pricing data. The approval clears the main clinical hurdle, but the commercial launch will test Roivant's ability to convert clinical success into sustainable revenue growth. Investors will be watching closely as the company begins its rollout.
